On October 23, 2023, Mr. Tony Kalajian resigned from all positions in Calidi Biotherapeutics, Inc., including his roles as Chief Accounting Officer and as interim Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.193 USD | -1.03% | +22.23% | -87.22% |
Apr. 16 | Calidi Biotherapeutics Prices $6.1 Million Offering | MT |
Mar. 21 | H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.22% | 9.45M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.99% | 22.25B | |
-14.77% | 21.68B | |
-9.05% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- CLDI Stock
- News Calidi Biotherapeutics, Inc.
- Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer